DE60019726D1 - Impfstofformulierung mit monoglyceriden oder fettsäuren als adjuvans - Google Patents

Impfstofformulierung mit monoglyceriden oder fettsäuren als adjuvans

Info

Publication number
DE60019726D1
DE60019726D1 DE60019726T DE60019726T DE60019726D1 DE 60019726 D1 DE60019726 D1 DE 60019726D1 DE 60019726 T DE60019726 T DE 60019726T DE 60019726 T DE60019726 T DE 60019726T DE 60019726 D1 DE60019726 D1 DE 60019726D1
Authority
DE
Germany
Prior art keywords
sub
formulation
fatty acids
vaccine
sup
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60019726T
Other languages
English (en)
Other versions
DE60019726T2 (de
Inventor
Ulf Schroeder
Stefan Svenson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EUROCINE STOCKHOLM AB
Original Assignee
EUROCINE STOCKHOLM AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by EUROCINE STOCKHOLM AB filed Critical EUROCINE STOCKHOLM AB
Application granted granted Critical
Publication of DE60019726D1 publication Critical patent/DE60019726D1/de
Publication of DE60019726T2 publication Critical patent/DE60019726T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
DE60019726T 1999-02-12 2000-02-09 Impfstofformulierung mit monoglyceriden oder fettsäuren als adjuvans Expired - Lifetime DE60019726T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9900496A SE9900496D0 (sv) 1999-02-12 1999-02-12 Vaccine formulation
SE9900496 1999-02-12
PCT/EP2000/001038 WO2000047224A2 (en) 1999-02-12 2000-02-09 Vaccine formulation comprising monoglycerides or fatty acids as adjuvant

Publications (2)

Publication Number Publication Date
DE60019726D1 true DE60019726D1 (de) 2005-06-02
DE60019726T2 DE60019726T2 (de) 2006-04-27

Family

ID=20414470

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60019726T Expired - Lifetime DE60019726T2 (de) 1999-02-12 2000-02-09 Impfstofformulierung mit monoglyceriden oder fettsäuren als adjuvans

Country Status (9)

Country Link
US (1) US6890540B1 (de)
EP (1) EP1150713B1 (de)
AT (1) ATE293993T1 (de)
AU (1) AU769375B2 (de)
DE (1) DE60019726T2 (de)
DK (1) DK1150713T3 (de)
NZ (1) NZ513129A (de)
SE (1) SE9900496D0 (de)
WO (1) WO2000047224A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2352671T3 (es) * 2002-11-26 2011-02-22 Eurocine Vaccines Ab Nuevo adyuvante a base de amina.
US7349378B2 (en) * 2003-02-24 2008-03-25 Toshiba America Research, Inc. Local area network resource manager
WO2005077409A1 (en) * 2004-02-18 2005-08-25 The University Of Newcastle Research Associates Limited A vaccine formulated for administration to mucosa of the lungs
DK1843787T3 (da) * 2005-01-28 2012-02-20 Univ Northwest Kombination af lipider og dinitrogenoxid som hjælpestof til forøgelse af vacciners virkningsgrad
US20090023682A1 (en) * 2007-07-19 2009-01-22 Joseph Artiss Composition Comprising Dietary Fat Complexer and Methods of Using Same
US8916164B2 (en) * 2007-08-29 2014-12-23 Abivax Methods of enhancing adjuvaticity of vaccine compositions
ES2519475T5 (es) * 2008-05-01 2018-07-02 Arecor Limited Formulación de una proteína
WO2010144794A1 (en) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Baculovirus-expressed fusion polypeptide vaccines with enhanced immunogenicity and uses thereof
CN102573883A (zh) 2009-06-12 2012-07-11 疫苗技术公司 用于促进细胞-介导的免疫应答的方法和组合物
WO2010144797A2 (en) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Influenza vaccines with enhanced immunogenicity and uses thereof
US20130115237A1 (en) 2010-06-09 2013-05-09 Vaccine Technologies, Incorporated Therapeutic immunization in hiv infected subjects to augment antiretroviral treatment
CN108840912B (zh) 2011-05-11 2023-07-04 儿童医疗中心有限公司 修饰的生物素结合蛋白及其融合蛋白和应用
EP2742952A1 (de) 2012-12-17 2014-06-18 Eurocine Vaccines AB Impfstoffzusammensetzung
CA2900008A1 (en) 2013-02-07 2014-08-14 Children's Medical Center Corporation Protein antigens that provide protection against pneumococcal colonization and/or disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4847080A (en) * 1984-03-07 1989-07-11 New York Blood Center, Inc. Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipide vesicle carriers
CA2017507C (en) * 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
SE9601158D0 (sv) * 1996-03-26 1996-03-26 Stefan Svenson Method of producing immunogenic products and vaccines
SE9602280D0 (sv) * 1996-06-10 1996-06-10 Pharmatrix Ab Immunstimulerande lipidformulering
US6350456B1 (en) * 1997-03-13 2002-02-26 Corixa Corporation Compositions and methods for the prevention and treatment of M. tuberculosis infection
KR20050086775A (ko) 2002-11-26 2005-08-30 푸로스트 인코포레이티드 트롤리 휘일용 저어널 베어링

Also Published As

Publication number Publication date
WO2000047224A2 (en) 2000-08-17
WO2000047224A3 (en) 2000-12-14
AU769375B2 (en) 2004-01-22
AU2547300A (en) 2000-08-29
ATE293993T1 (de) 2005-05-15
EP1150713B1 (de) 2005-04-27
DE60019726T2 (de) 2006-04-27
EP1150713A2 (de) 2001-11-07
SE9900496D0 (sv) 1999-02-12
US6890540B1 (en) 2005-05-10
NZ513129A (en) 2003-01-31
DK1150713T3 (da) 2005-08-29

Similar Documents

Publication Publication Date Title
DE60019726D1 (de) Impfstofformulierung mit monoglyceriden oder fettsäuren als adjuvans
CY1110140T1 (el) Εμβολιασμος με μηνιγγοκοκκικο συζευγμα
JP2002501033A5 (de)
ATE58292T1 (de) L-dopa enthaltendes arzneimittel.
SE9600716D0 (sv) Adhesion inhibitors, preparation comprising them and method for producing them
SE9602280D0 (sv) Immunstimulerande lipidformulering
DK0584126T3 (da) Lanolinderivater som penetrationsfremmende stoffer
ATE342065T1 (de) Impfstofformulierung gegen tuberkulose mit monoglyceriden oder fettsäuren als adjuvant
ATE108487T1 (de) Herstellung eines desoxyribonucleosids.
WO1993013797A3 (en) Detoxified lps-cholera toxin conjugate vaccine for prevention of cholera
SE9601158D0 (sv) Method of producing immunogenic products and vaccines
FI932759A0 (fi) Anvaendningen av IL-4 foer oekning av pao vacciners immunogener verkande immunreaktioner
Tsujimoto et al. Adjuvant activity of 6-O-acyl-muramyldipeptides to enhance primary cellular and humoral immune responses in guinea pigs: dose-response and local reactions observed with selected compounds
SE0100011D0 (sv) Virus vaccine formulation
DE60024326D1 (de) Lipide zur stimulierung der immunreaktion
Ruzgiene et al. Study of L-ornithine decarboxylase synthesis in different strains of the Vibrionaceae family.
Hadley The design of heterologous enzymes suitable for therapeutic application.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition